Track topics on Twitter Track topics that are important to you
The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...
KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...
AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...
BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...
Regulus Therapeutics San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeut...
Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.
Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).
Akcea Therapeutics plans to raise up to $100m through an initial public offering of its common stock shares.
NewsRespira Therapeutics announces collaboration with United Therapeutics to treat pulmonary hypertension. The agreement involves the development and exclusive license of Respira's inhaled drug-device...
About Arcturus Therapeutics, Inc. Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies Read more...
Michael Kavanaugh, MD, Chief Scientific Officer of CytomX Therapeutics CytomX Therapeutics' novel Probody Platform allows the design of drugs that take advantage of unique Read more...